犹他州允许AI在无直接人工监督下为患者检查和开药

犹他州医疗初创公司Nolla Health推出了美国首个由人工智能独立完成患者检查和药物处方的项目1。该项目目前针对轻度至中度痤疮患者，为期一年，患者通过月费4.99美元的应用程序扫描面部后，由AI进行分析并从八种已批准的局部用药中推荐一种1。

项目分阶段逐步减少人工监督比例1。前100份处方需要医生审核后才能提交药房1；之后的400名患者处方由AI直接提交，医生每周进行回顾审核1；最终阶段医生每月审核已发布处方的至少10%1。Nolla Health首席执行官Luis Wenus表示，这八种药物的不良反应仅限于局部皮肤刺激或干燥1。

Nolla Health, a healthcare startup based in Utah, has launched what is believed to be the first program in the United States allowing artificial intelligence to independently examine patients and prescribe medication without direct human supervision.1 The initiative, currently limited to treating mild to moderate acne, represents a significant shift in how medical decision-making may be delegated to algorithms in the state.

Under the one-year pilot program, patients pay a monthly subscription of $4.99 to use an application that scans their face, with AI analyzing the images and recommending one of eight approved topical medications.1 The rollout is structured in three phases with decreasing levels of physician oversight. During the first phase, the initial 100 prescriptions require doctor review before being submitted to pharmacies.1 In the second phase, prescriptions for the next 400 patients are submitted directly by the AI while physicians conduct weekly reviews.1 By the third phase, doctors are required to review at least 10 percent of dispensed prescriptions on a monthly basis.1

According to Nolla Health CEO Luis Wenus, the eight approved medications carry side effects limited to localized skin irritation or dryness.1 The restricted scope and controlled rollout reflect the regulatory constraints governing this early experiment in autonomous AI-driven medical practice.